Champions Oncology, Inc. (CSBR) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Bionano Genomics, Inc.

CARA Therapeutics, Inc.

C4 Therapeutics, Inc.

Carmell Corp.

Champions Oncology, Inc.

Compugen Ltd.

Kodiak Sciences, Inc.

IO Biotech, Inc.

Anixa Biosciences, Inc.

Kezar Life Sciences, Inc.

Spruce Biosciences, Inc.

Why is Champions Oncology, Inc. ?

Underperformed the market in the last 1 year

Even though the market (S&P 500) has generated returns of 15.98% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -12.82% returns

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Champions Oncology, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Champions Oncology, Inc.

-100.0%

0.66

78.73%

S&P 500

13.99%

0.81

19.85%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

12.13%

EBIT Growth (5y)

39.59%

EBIT to Interest (avg)

-1.09

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.30

Sales to Capital Employed (avg)

6.14

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

43.86%

ROCE (avg)

40.85%

ROE (avg)

24.39%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

17.42

EV to EBIT

13.93

EV to EBITDA

10.75

EV to Capital Employed

24.29

EV to Sales

1.60

PEG Ratio

0.09

Dividend Yield

ROCE (Latest)

174.42%

ROE (Latest)

117.52%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bullish

Mildly Bearish

Dow Theory

Bearish

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

15What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD 7.39 MM

NET PROFIT(HY)

Higher at USD 2.66 MM

ROCE(HY)

Highest at 503.05%

-16What is not working for the Company

RAW MATERIAL COST(Y)

Grown by 21.73% (YoY

DEBTORS TURNOVER RATIO(HY)

Lowest at 5.49 times

NET SALES(Q)

Lowest at USD 12.36 MM

OPERATING PROFIT(Q)

Lowest at USD -1.32 MM

OPERATING PROFIT MARGIN(Q)

Lowest at -10.68 %

PRE-TAX PROFIT(Q)

Lowest at USD -1.96 MM

NET PROFIT(Q)

Lowest at USD -1.83 MM

EPS(Q)

Lowest at USD -0.13

Here's what is working for Champions Oncology, Inc.

Operating Cash Flow

Highest at USD 7.39 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Here's what is not working for Champions Oncology, Inc.

Pre-Tax Profit

At USD -1.96 MM has Fallen at -222.75%

over average net sales of the previous four periods of USD 1.6 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -1.83 MM has Fallen at -214.21%

over average net sales of the previous four periods of USD 1.61 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Net Sales

At USD 12.36 MM has Fallen at -15.65%

over average net sales of the previous four periods of USD 14.65 MM

MOJO Watch

Near term sales trend is very negative

Net Sales (USD MM)

Net Sales

Lowest at USD 12.36 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (USD MM)

Operating Profit

Lowest at USD -1.32 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (USD MM)

Operating Profit Margin

Lowest at -10.68 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Pre-Tax Profit

Lowest at USD -1.96 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit

Lowest at USD -1.83 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

EPS

Lowest at USD -0.13

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (USD)

Debtors Turnover Ratio

Lowest at 5.49 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Raw Material Cost

Grown by 21.73% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales